Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levallorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 10/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.86 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.69 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.69 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.69 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.69 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.69 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.69 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.69 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levallorphan SCHEMBL20505815 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL12232843 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL29368769 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL34060 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL12233279 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL16311899 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Dextallorphan SCHEMBL29438705 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL678413 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL8459964 | 0.99 | OPRM1 (0.98) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL5675160 | 0.97 | OPRM1 (0.94) | OPRM1OPRK1KCNH2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1754712-A2 | Transcobalamin binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1416920-B1 | MULTIPLEX DRUG DELIVERY SYSTEM SUITABLE FOR ORAL ADMINISTRATION | IMPAX PHARMACEUTICALS INC (US) | 2007-01-10 | — | — | EP | claimed |
| US-20060166862-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2006-07-27 | — | — | US | claimed |
| EP-1416920-A4 | MULTIPLEX DRUG DELIVERY SYSTEM SUITABLE FOR ORAL ADMINISTRATION | IMPAX PHARMACEUTICALS INC (US) | 2004-05-12 | — | — | EP | claimed |
| EP-1416920-A2 | MULTIPLEX DRUG DELIVERY SYSTEM SUITABLE FOR ORAL ADMINISTRATION | Impax Pharmaceuticals Inc. (US) | 2004-05-12 | — | — | EP | claimed |
| US-6730321-B2 | FOR TABLETS; COMPRESSION BLEND; SUSTAINED RELEASE | IMPAX PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| US-20030203028-A1 | Multiplex drug delivery system suitable for oral administration | IMPAX PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | claimed |
| EP-1334114-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2003-08-13 | — | — | EP | claimed |
| US-20020164371-A1 | Press coated, pulsatile drug delivery system suitable for oral administration | IMPAX PHARMACEUTICALS INC. | 2002-11-07 | — | — | US | claimed |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | COLLINS DOUGLAS A (US) | 2002-10-17 | — | — | US | claimed |
| WO-2002055530-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION (US) | 2002-07-18 | — | — | WO | claimed |
| US-6372254-B1 | Press coated, pulsatile drug delivery system suitable for oral administration | IMPAX PHARMACEUTICALS INC. | 2002-04-16 | — | — | US | claimed |
| WO-2000018447-A2 | MULTIPLEX DRUG DELIVERY SYSTEM SUITABLE FOR ORAL ADMINISTRATION | IMPAX PHARMACEUTICALS, INC. (US) | 2000-04-06 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| EP-3666261-B1 | PHARMACEUTICAL TABLET AND METHOD FOR PRODUCING SAME | MITSUBISHI CHEM CORP (JP) | 2025-01-15 | — | — | EP | disclosed |
| US-20240145031-A1 | Methods and devices for drug repositioning and drug repurposing as nuclear receptor modulators | Precision Medicine Lab (NL) | 2024-05-02 | — | — | US | disclosed |
| EP-0077393-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | The University of Kentucky Research Foundation (US) | 1983-04-27 | — | — | EP | disclosed |
| WO-1982003768-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | UNIV KENTUCKY (US) | 1982-11-11 | — | — | WO | disclosed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166862-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | OPRM1 2385/4885OPRK1 1860/4885KCNH2 4699/4885 |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | OPRM1 2385/4885OPRK1 1860/4885KCNH2 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.